Overview
- Editors:
-
-
Benny K. C. Lo
-
MRC Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
Access this book
Other ways to access
Table of contents (32 protocols)
-
-
Antibody Sequence And Structure
-
-
- Benny K. C. Lo, Yu Wai Chen
Pages 3-9
-
- George Johnson, Tai Te Wu
Pages 11-25
-
-
- Nicholas Whitelegg, Anthony R. Rees
Pages 51-91
-
- Stephen E. Harding, Emma Longman, Beatriz Carrasco, Alvaro Ortega, Jose Garcia de la Torre
Pages 93-113
-
Antibody-Lead Generation
-
Front Matter
Pages 115-115
-
- James D. Marks, Andrew Bradbury
Pages 117-134
-
-
- James D. Marks, Andrew Bradbury
Pages 161-176
-
- Mingyue He, Neil Cooley, Alison Jackson, Michael J. Taussig
Pages 177-189
-
- C. Geoffrey Davis, Xiao-Chi Jia, Xiao Feng, Mary Haak-Frendscho
Pages 191-200
-
-
-
- Roland E. Kontermann, Tina Völkel, Tina Korn
Pages 227-242
-
Antibody Expression And Optimization
-
Front Matter
Pages 243-243
-
-
- Paul J. Yazaki, Anna M. Wu
Pages 255-268
-
- Mary C. Guttieri, Mifang Liang
Pages 269-299
About this book
The exquisite binding specificity of antibodies has made them valuable tools from the laboratory to the clinic. Since the description of the murine hybridoma technology by Köhler and Milstein in 1975, a phenomenal number of mo- clonal antibodies have been generated against a diverse array of targets. Some of these have become indispensable reagents in biomedical research, while others were developed for novel therapeutic applications. The attractiveness of an- bodies in this regard is obvious—high target specificity, adaptability to a wide range of disease states, and the potential ability to direct the host’s immune s- tem for a therapeutic response. The initial excitement in finding Paul Ehrlich’s “magic bullet,” however, was met with widespread disappointment when it was demonstrated that murine antibodies frequently elicit the human anti-murine an- body (HAMA) response, thus rendering them ineffective and potentially unsafe in humans. Despite this setback, advances in recombinant DNA techniques over the last 15–20 years have empowered the engineering of recombinant antibodies with desired characteristics, including properties to avoid HAMA. The ability to p- duce bulk quantities of recombinant proteins from bacterial fermentation also fueled the design of numerous creative antibody constructs. To date, the United States Food and Drug Administration has approved more than 10 recombinant antibodies for human use, and hundreds more are in the development pipeline. The recent explosion in genomic and proteomic information appears ready to deliver many more disease targets amenable to antibody-based therapy.
Reviews
"...as the book provides as comprehensive collection of clear, detailed methods it is very likely to prove its worth as a laboratory reference." - Immunology News
"...a valuable addition to in-lab books" - Microbiology Today
Editors and Affiliations
-
MRC Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
Benny K. C. Lo
